{"id":"NCT02285062","sponsor":"Celgene","briefTitle":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","officialTitle":"Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-17","primaryCompletion":"2019-03-15","completion":"2022-07-28","firstPosted":"2014-11-06","resultsPosted":"2020-03-30","lastUpdate":"2023-06-22"},"enrollment":570,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Large B-Cell, Diffuse"],"interventions":[{"type":"DRUG","name":"lenalidomide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"prednisone","otherNames":[]},{"type":"DRUG","name":"vincristine","otherNames":[]}],"arms":[{"label":"R2-CHOP","type":"EXPERIMENTAL"},{"label":"R-CHOP","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.","primaryOutcome":{"measure":"Kaplan-Meier Estimate of Progression Free Survival (PFS)","timeFrame":"From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months","effectByArm":[{"arm":"Lenalidomide Plus R-CHOP (R2-CHOP)","deltaMin":null,"sd":null},{"arm":"Placebo Plus R-CHOP","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2864"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":158,"countries":["United States","Australia","Belgium","Canada","China","Czechia","France","Ireland","Israel","Italy","Japan","Netherlands","New Zealand","Portugal","Puerto Rico","Russia","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["27089170","39563886","33621109"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":104,"n":283},"commonTop":["Neutropenia","Anaemia","Constipation","Nausea","Thrombocytopenia"]}}